[Carbapenems (thienam and Meronem). Their clinical and economic efficacy].
The authors describe 229 cases of carbapenem use in intensive care wards. Tienam was used in 205 cases since 1993, meronem in 24 cases since 1996. There were 149 men and 80 women aged 15-76 years (mean age 46.4 +/- 0.7 years). Carbapenemes were administered by 5-7-day courses in a daily dose of 2-6 g (2-4 g for tienam and 2-6 g for meronem). Carbapenemes were administered as monotherapy; in 196 cases nisoral was added to antibiotic therapy starting from day 3 as an antimycotic agent. Bacteriological studies were carried out in 367 patients (413 inoculations). Sensitivity of cultured microflora to disks with tienam (329 tests) and meronem (97 tests) showed their high activity towards gram-positive and gram-negative flora. The results were less demonstrative in cerebral abscesses, which is explained by specific pharmacokinetics of tienam. Analysis of the cost/efficacy ratio confirmed the economic efficacy of this group of drugs.